DARPin based multi-specific t-cell engagers
US11834504B2 · kind B2 · utility
0Cited by
14References
21Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 9, 2022 |
| Grant date | Dec 5, 2023 |
| Priority date | — |
| Expiry date | Mar 9, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to recombinant multi-specific proteins comprising binding agents with binding specificity for different targets, such as, e.g. CD3, CD33, CD123 and CD70. In addition, the invention relates to nucleic acids encoding such multi-specific proteins, pharmaceutical compositions comprising such proteins or nucleic acids, and the use of such binding proteins, nucleic acids or pharmaceutical compositions in methods for treating or diagnosing diseases, such as cancer, e.g. acute myeloid leukaemia (AML), in a mammal, including a human.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.